Literature DB >> 2872839

Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium.

S M Rupp, J W McChristian, R D Miller, J A Taboada, R Cronnelly.   

Abstract

To compare the time course of neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium, the authors studied 98 patients anesthetized with nitrous oxide (60%) and halothane or enflurane. Neuromuscular blockade, as monitored by single stimulus-induced twitch tension (TT), was antagonized at varying degrees of spontaneous recovery (2-80% of control TT). Time to antagonism (time from injection of neostigmine or edrophonium to 90% recovery of control TT) was not different between edrophonium, 0.5 mg/kg, and neostigmine, 0.04 mg/kg, when spontaneous recovery had been allowed to occur to at least 11% of control TT prior to antagonist administration (P greater than 0.05). For profound neuromuscular blockade (TT less than or equal to 10% of control) induced by pancuronium or vecuronium, time (mean +/- SD) to antagonism with neostigmine, 0.04 mg/kg, was 7.0 +/- 2.2 min and 5.6 +/- 1.7 min, respectively, while the same for edrophonium, 0.5 mg/kg, was 20.0 +/- 8.0 min and 15.0 +/- 12.5 min, respectively (P less than 0.05). Time to antagonism of profound atracurium-induced neuromuscular blockade was 8.5 +/- 3.3 min for neostigmine, 0.04 mg/kg, and 9.8 +/- 7.0 min for edrophonium, 0.5 mg/kg, (P less than 0.05). For profound vecuronium-and pancuronium-induced neuromuscular blockade, time to antagonism by edrophonium, 1.0 mg/kg, was 4.6 +/- 3.0 min and 3.9 +/- 1.6 min respectively. The authors conclude that neostigmine, 0.04 mg/kg, antagonizes neuromuscular blockade within 12 min when TT is greater than 2% of control at time of reversal. When TT is greater than 10% of control, edrophonium, 0.5 mg/kg, produces similar time to antagonism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872839     DOI: 10.1097/00000542-198606000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

Review 1.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 2.  Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.

Authors:  D Faulds; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Priming with anti-cholinesterases--the effect of different combinations of anti-cholinesterases and different priming intervals.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

4.  Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade.

Authors:  H Kirkegaard-Nielsen; H S Helbo-Hansen; P Lindholm; I K Severinsen; H S Pedersen; E W Jensen
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

5.  Priming with anti-cholinesterases--the effect of different priming doses of edrophonium.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

6.  Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade.

Authors:  F Donati; J Lahoud; D McCready; D R Bevan
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

Review 7.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

8.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.